Q4 Earnings Forecast for KALV Issued By Leerink Partnrs

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for KalVista Pharmaceuticals in a report released on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz expects that the specialty pharmaceutical company will post earnings of ($0.77) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals' Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.41) EPS and FY2027 earnings at ($1.27) EPS.

A number of other research firms have also commented on KALV. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a "buy" rating and a $22.00 price objective for the company. Jones Trading reissued a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $24.83.

Remove Ads

KalVista Pharmaceuticals Trading Up 0.1 %

KALV stock traded up $0.02 during mid-day trading on Friday, reaching $11.56. 261,044 shares of the stock traded hands, compared to its average volume of 386,856. The stock's fifty day moving average is $10.63 and its 200-day moving average is $10.25. The company has a market cap of $574.52 million, a P/E ratio of -3.16 and a beta of 0.76. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the transaction, the chief executive officer now owns 287,811 shares in the company, valued at $3,445,097.67. This trade represents a 2.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Paul K. Audhya sold 3,125 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the sale, the insider now owns 100,334 shares of the company's stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KALV. Suvretta Capital Management LLC increased its position in KalVista Pharmaceuticals by 16.6% during the fourth quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock worth $41,613,000 after acquiring an additional 701,007 shares during the period. Tang Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 13.2% during the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock worth $41,451,000 after purchasing an additional 572,300 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in shares of KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock worth $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP raised its position in shares of KalVista Pharmaceuticals by 19.3% during the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after buying an additional 770,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of KalVista Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company's stock valued at $19,102,000 after buying an additional 104,716 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).